| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.9 |